Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2001-03, Vol.7 (2), p.160-163
• Main Authors: Dykes, A. C., Walker, I. D., Lowe, G. D. O., Tait, R. C.
• Format: Article
• Language: English
• Subjects: acquired haemophilia; Aged; Aged, 80 and over; Antibodies, Anticardiolipin - blood; Disease-Free Survival; Drug Therapy, Combination; factor VIII; Factor VIII - antagonists & inhibitors; Factor VIII - immunology; factor VIII inhibitor; Female; Humans; Immunoglobulin G - blood; Immunoglobulin M - blood; Immunoglobulins, Intravenous - administration & dosage; Immunoglobulins, Intravenous - standards; immunosuppressive therapy; Isoantibodies - blood; Isoantibodies - drug effects; Lupus Coagulation Inhibitor - blood; Male; Partial Thromboplastin Time; Prednisolone - administration & dosage; Prednisolone - standards; Treatment Outcome
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1046/j.1365-2516.2001.00489.x

Acquired inhibitors to factor VIII (FVIII) are rare, but life‐threatening in up to 22% of cases. The optimal therapy for suppression of these inhibitors remains unclear. Prednisolone is the mainstay of therapy, producing responses in approximately 30% of cases. Intravenous immunoglobulin (IVIg) has a similar response rate, but a more rapid effect. We report the results of prednisolone 1 mg kg−1 combined with IVIg 2 g kg−1 in divided doses as first‐line therapy in seven consecutive patients with acquired FVIII inhibitors. All patients were bleeding at the time of diagnosis with prolonged activated partial thromboplastin time. There were four complete responses, one partial response, one nonresponse and one with an inadequate follow‐up for assessment of response, giving an overall response rate of 71%. In all complete responders the inhibitor declined rapidly and was undetectable by day 21 from start of treatment. Therapy was well tolerated and responses have been maintained off treatment for 2–8 months. This is a safe, well‐tolerated rapidly acting regimen with good response rates.